Market Cap 129.01M
Revenue (ttm) 7.95M
Net Income (ttm) -21.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -267.04%
Debt to Equity Ratio 0.00
Volume 232,357
Avg Vol 175,610
Day's Range N/A - N/A
Shares Out 23.46M
Stochastic %K 99%
Beta 0.61
Analysts Strong Sell
Price Target $15.19

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
zampy
zampy Jun. 30 at 6:00 PM
$COYA Yesterday the VWAP was $5.75 ..TIDAY higher at $$6..... great sign
0 · Reply
john_Ennis
john_Ennis Jun. 30 at 2:11 PM
$COYA such low volume. Don't people watch good morning America anymore ?
1 · Reply
microcapspeculator
microcapspeculator Jun. 30 at 1:56 PM
$COYA Just saw the Chris Johnson piece on the news. If his doctor says he has shown improvement it is obvious he is on Coya-302. He is at the stage where placebo is not going to have any effect.
0 · Reply
Jwa68
Jwa68 Jun. 30 at 3:09 AM
$GANX In my mind, it's not if, but who, when and how much they ultimately pay for Gain. Only way out for pharma is to acquire their way out. Not speculation, but a simple fact. Both it and $COYA will have new names on the door soon enough.
0 · Reply
microcapspeculator
microcapspeculator Jun. 30 at 3:05 AM
$COYA Great evidence that Coya-302 is working. While this is a blind placebo controlled study you cant fool ALS for long as it is a devastating disease. No doctor would make these types of comments unless the patient has been on the drug for a while and has shown true benefits. Just like all the previous studies it works and also works for FTD. Someone needs to buy them before that study launches.
0 · Reply
Ihavesunshineinmypocket
Ihavesunshineinmypocket Jun. 30 at 1:14 AM
0 · Reply
Jwa68
Jwa68 Jun. 30 at 12:20 AM
$ABCL $GANX $COYA Nice day for all three and let us not forget $SLS. Bio is seeing big inflows and smaller names are all acquisition targets.
0 · Reply
GodFamilyFriends
GodFamilyFriends Jun. 29 at 10:24 PM
$COYA Breakout
0 · Reply
Jwa68
Jwa68 Jun. 29 at 10:23 PM
$COYA $GANX Stay the course and remember... Coya just recieved fast track designation. One would think Gain may soon receive the same now that the IND was accepted. Both companies likely have new names on the door by year end in my mind. Billionaire investor David Einhorn owns large positions in both, his two smallest cap investments. DYDD
0 · Reply
vo2macs
vo2macs Jun. 29 at 8:14 PM
$COYA Long term down trend just broke. Who's buying?
1 · Reply
Latest News on COYA
Coya Therapeutics Transcript: AGM 2026

Jun 25, 2026, 1:00 PM EDT - 5 days ago

Coya Therapeutics Transcript: AGM 2026


Coya Therapeutics Transcript: Investor update

Jun 24, 2026, 4:00 PM EDT - 5 days ago

Coya Therapeutics Transcript: Investor update


Coya Therapeutics initiated with a Buy at Roth Capital

2026-06-05T08:20:06.000Z - 25 days ago

Coya Therapeutics initiated with a Buy at Roth Capital


Coya Therapeutics Slides: Investor presentation

Jun 1, 2026, 7:00 AM EDT - 4 weeks ago

Coya Therapeutics Slides: Investor presentation


Coya Therapeutics Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Coya Therapeutics Proxy statement: Proxy filing


Coya Therapeutics Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Coya Therapeutics Proxy statement: Proxy filing


Coya Therapeutics reports Q1 EPS (32c), consensus (39c)

2026-05-12T11:49:47.000Z - 7 weeks ago

Coya Therapeutics reports Q1 EPS (32c), consensus (39c)


Coya Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Coya Therapeutics Earnings release: Q1 2026


Coya Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Coya Therapeutics Quarterly report: Q1 2026


Coya Therapeutics Slides: Investor presentation

May 11, 2026, 2:00 AM EDT - 7 weeks ago

Coya Therapeutics Slides: Investor presentation


Coya Therapeutics Slides: Corporate presentation

May 1, 2026, 7:00 AM EDT - 2 months ago

Coya Therapeutics Slides: Corporate presentation


Coya Therapeutics announces publication of research on COYA 302

2026-04-09T12:26:37.000Z - 2 months ago

Coya Therapeutics announces publication of research on COYA 302


Coya Therapeutics Executive Chairman Howard Berman steps down

2026-04-02T12:17:50.000Z - 3 months ago

Coya Therapeutics Executive Chairman Howard Berman steps down


Coya Therapeutics Slides: Investor presentation

Apr 2, 2026, 7:00 AM EDT - 3 months ago

Coya Therapeutics Slides: Investor presentation


Coya Therapeutics Annual report: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Annual report: Q4 2025


Coya Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Earnings release: Q4 2025


Coya Therapeutics Registration statement: Registration Filing

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Registration statement: Registration Filing


Coya Therapeutics Transcript: Status update

Feb 17, 2026, 3:00 PM EST - 4 months ago

Coya Therapeutics Transcript: Status update


Coya Therapeutics Slides: Status update

Feb 17, 2026, 3:00 PM EST - 4 months ago

Coya Therapeutics Slides: Status update


Coya Therapeutics Announces $11.1 Million Private Placement

Jan 30, 2026, 8:00 AM EST - 5 months ago

Coya Therapeutics Announces $11.1 Million Private Placement


Coya Therapeutics commences dosing in ALSTARS trial

2025-12-09T13:11:58.000Z - 7 months ago

Coya Therapeutics commences dosing in ALSTARS trial


Coya Therapeutics Slides: Investor Presentation

Nov 30, 2025, 6:00 PM EST - 7 months ago

Coya Therapeutics Slides: Investor Presentation


Coya Therapeutics reports Q3 EPS (13c), consensus (30c)

2025-11-12T13:20:43.000Z - 8 months ago

Coya Therapeutics reports Q3 EPS (13c), consensus (30c)


Coya Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Coya Therapeutics Quarterly report: Q3 2025


Coya Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Coya Therapeutics Earnings release: Q3 2025


Coya Therapeutics 3.64M Spot Secondary priced at $5.50

2025-10-24T10:35:20.000Z - 8 months ago

Coya Therapeutics 3.64M Spot Secondary priced at $5.50


Coya Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Earnings release: Q2 2025


Coya Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Quarterly report: Q2 2025


Coya Therapeutics Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Registration statement: Registration Filing


Coya Therapeutics Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Proxy statement: Proxy Filing


Coya Therapeutics Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Proxy statement: Proxy Filing


Coya Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Quarterly report: Q1 2025


Coya Therapeutics Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q1 2025


Coya Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Annual report: Q4 2024


Coya Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q4 2024


zampy
zampy Jun. 30 at 6:00 PM
$COYA Yesterday the VWAP was $5.75 ..TIDAY higher at $$6..... great sign
0 · Reply
john_Ennis
john_Ennis Jun. 30 at 2:11 PM
$COYA such low volume. Don't people watch good morning America anymore ?
1 · Reply
microcapspeculator
microcapspeculator Jun. 30 at 1:56 PM
$COYA Just saw the Chris Johnson piece on the news. If his doctor says he has shown improvement it is obvious he is on Coya-302. He is at the stage where placebo is not going to have any effect.
0 · Reply
Jwa68
Jwa68 Jun. 30 at 3:09 AM
$GANX In my mind, it's not if, but who, when and how much they ultimately pay for Gain. Only way out for pharma is to acquire their way out. Not speculation, but a simple fact. Both it and $COYA will have new names on the door soon enough.
0 · Reply
microcapspeculator
microcapspeculator Jun. 30 at 3:05 AM
$COYA Great evidence that Coya-302 is working. While this is a blind placebo controlled study you cant fool ALS for long as it is a devastating disease. No doctor would make these types of comments unless the patient has been on the drug for a while and has shown true benefits. Just like all the previous studies it works and also works for FTD. Someone needs to buy them before that study launches.
0 · Reply
Ihavesunshineinmypocket
Ihavesunshineinmypocket Jun. 30 at 1:14 AM
0 · Reply
Jwa68
Jwa68 Jun. 30 at 12:20 AM
$ABCL $GANX $COYA Nice day for all three and let us not forget $SLS. Bio is seeing big inflows and smaller names are all acquisition targets.
0 · Reply
GodFamilyFriends
GodFamilyFriends Jun. 29 at 10:24 PM
$COYA Breakout
0 · Reply
Jwa68
Jwa68 Jun. 29 at 10:23 PM
$COYA $GANX Stay the course and remember... Coya just recieved fast track designation. One would think Gain may soon receive the same now that the IND was accepted. Both companies likely have new names on the door by year end in my mind. Billionaire investor David Einhorn owns large positions in both, his two smallest cap investments. DYDD
0 · Reply
vo2macs
vo2macs Jun. 29 at 8:14 PM
$COYA Long term down trend just broke. Who's buying?
1 · Reply
Thebullsafool
Thebullsafool Jun. 29 at 8:14 PM
$COYA Got in early here at 4.60 after all the cross posts from Ganx - very happy! amazing company, amazing team, amazing returns
0 · Reply
EmotionlessRobot
EmotionlessRobot Jun. 29 at 8:00 PM
$COYA If you're new: https://medium.com/@killian.sheehan/the-100-million-anomaly-why-david-einhorn-chose-a-nobel-prize-biotech-over-the-ai-bubble-a9f4d1ff1740
0 · Reply
Jwa68
Jwa68 Jun. 29 at 7:41 PM
1 · Reply
Jwa68
Jwa68 Jun. 29 at 7:25 PM
$COYA https://youtu.be/vGdqmYPwRu4?is=1cGA3tt4rh02SSFu
1 · Reply
Jwa68
Jwa68 Jun. 29 at 7:04 PM
$COYA Well well well...
4 · Reply
irf944
irf944 Jun. 29 at 6:39 PM
$COYA Dr. Merit Cudkowicz is Executive Director of the MGH Brigham Neuroscience Institute and Director of the Sean M. Healey & AMG Center for ALS at Mass General and listed as an expert clinical advisor to Coya, providing ALS-development expertise for COYA 302. Coya has an active ALSTARS Phase 2 COYA 302 ALS trial site at MGH. Mass General has an official donation page in honor of Chris Johnson supporting the Sean M. Healey & AMG Center for ALS—the MGH ALS center led by Dr. Merit Cudkowicz. Public reporting indicates that Dr. Merit Cudkowicz is working with Chris Johnson on his ALS care and clinical-trial treatment Very interesting connections to Chris Johnson, MGH and Coya. Sounds like he is getting top care and glad to see our own Dr. Cudkowicz involved.
1 · Reply
zampy
zampy Jun. 29 at 6:38 PM
$COYA Dr Merit Cudkowicz who was on the Good Morning America segment was brought on by COYA July 23rd 2023 and believes in the Tregs and putting out fire abatacept therapy. The above is accurate...I believe its COYA treating Chris Johnson.
0 · Reply
zampy
zampy Jun. 29 at 6:18 PM
$COYA Dr Merit Cudkowicz treating Superstar NFL Player Chris Johnson was brought in by COYA ....I am fairly certain of that in my opinion. The Interview stated at Mass General helping Chris with his inflammation. It sounds to me Tregs are getting enhanced and the bad guys being supressed.
1 · Reply
irf944
irf944 Jun. 29 at 6:11 PM
$COYA Point & Figure chart update. With today's price action we had a Triple Top Breakout on the P&F chart, AND we broke thru the long term resistance line. This is an EXTREMELY Bullish breakout on a P&F chart A reasonable historical benchmark is about 70%–72% positive after a Point & Figure Triple Top Breakout. One commonly cited Dorsey Wright-based statistic puts the success rate at 72%, with an average gain of about 21% for successful triple-top breakouts. The next area of resistance is around $7.00 which happens to also be the 20% above the current price. Coya is in a solid financial position with about $50.7 million in cash as after an $11.1 million private placement led largely by Dr. Reddy’s who has partnered up with them. FDA granted them Fast Track designation for COYA 302.
2 · Reply
Will2ride1
Will2ride1 Jun. 29 at 5:54 PM
$COYA 📈👁
0 · Reply
Chootinblanks
Chootinblanks Jun. 29 at 4:01 PM
$COYA Another devastating diagnosis to bring attention to this awful disease. https://www.espn.com/nfl/story/_/id/49214999/former-nfl-rb-chris-johnson-discusses-als-diagnosis
1 · Reply
Jwa68
Jwa68 Jun. 29 at 2:29 PM
$ABCL $GANX $COYA Nice little trifecta of opportunity in bio.
1 · Reply